GVS S.p.A (GVS) Fair Value & Analysis
Industrials · IT · Market cap €805M
Fair value as of: Jul 16, 2026
From 23 valuation models · updated 25 days ago
Share price +15.1% over the past month.
A solid business, but screening 60% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€2.58). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range €3.00 – €16.85 · fair‑value band €1.55 – €2.58 · the €4.89 price screens above the €1.97 fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
GVS S.p.A (GVS) currently trades at €4.89, while our model-based Fair Value estimate is €1.97, implying the stock looks roughly 59.7% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, GVS S.p.A generated revenue of €422M at a net margin of 6.6%. Revenue declined 2.1% year over year. It earns a return on equity of 6.2%. Net debt stands at €210M. Fundamentals as of Jul 16, 2026
Our scenario range runs from €1.55 (bear case) to €2.58 (bull case); at €4.89, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 48% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -48% fair-value upside, at -60%, GVS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models (€2.08) versus Growth DCF (€0.3700). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GVS S.p.A., together with its subsidiaries, produces and sells filter solutions for applications in the healthcare and life sciences, energy and mobility, and health and safety sectors in Italy and internationally.
Full company description
GVS S.p.A., together with its subsidiaries, produces and sells filter solutions for applications in the healthcare and life sciences, energy and mobility, and health and safety sectors in Italy and internationally. The company offers health and safety products, such as hand dryer and vacuum cleaner filters; nailstation COSMO products; fume extraction and HVAC building products; and disposable masks, half masks, integra masks, powered air purifying respirators, face fit testing, replacement filters, supplied air respirators, spare parts, and accessories. It also provides autoclave filters, insufflation and ventilation filters and kits, machine filters, respiratory and anesthesia filters, smoke evacuation filters and kits, spirometry filters and accessories, suction filters, and tracheal humidifier filters; healthcare liquid products, such as bacterial air vents, blood tubular filters, infusion disc filters, IV and liquid filters, IV flow regulators, medical bags and components, sterile infusion sets and accessories, stopcock and manifold products, and transducer protectors; and capsule and cartridge filters, disc and sheet membranes, mini roll membranes, DNA/RNA test kits, filter papers, microbiology products, microfiltration devices, microporous and track etched roll membranes, protein microarrays, and environmental monitoring products, as well as western blotting membranes and reagents. In addition, the company offers energy and mobility products, such as fuel tanks and pumps, metal components, reservoirs, and SCR urea systems; ABS, ESP, and brake systems; EV applications and batteries; injection, tank vapour ventilation, and transmission products; ventilation systems; and cabin air and HVAC systems, and engine air intake ventilation filters. The company was formerly known as GVS S.r.l. and changed its name to GVS S.p.A. in 2001. GVS S.p.A. was founded in 1979 and is headquartered in Zola Predosa, Italy. GVS S.p.A. operates as a subsidiary of GVS Group S.r.l.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GVS S.p.A reported revenue of €425M in FY2025 versus €340M in FY2021, a compound +5.7%/yr. Reported net income was €18.4M in FY2025, compounding −27.7%/yr from FY2021.
GVS screens 60% overvalued. Compare with Veralto Corporation →
Peer Group
Pollution & Treatment Controls · 91 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pollution & Treatment Controls median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veralto Corporation VLTO | $94.21 | $69.11 | -27% |
| Zurn Elkay Water Solutions Corporation ZWS | $47.63 | $24.92 | -48% |
| Canmax Technologies Co 300390 | ¥57.02 | ¥10.41 | -82% |
| CECO Environmental Corp CECO | $83.63 | $15.19 | -82% |
| Fujian Longking Co 600388 | ¥17.58 | ¥15.59 | -11% |
| Munters Group MTRS | kr 166.60 | kr 16.90 | -90% |
| China Conch Venture Holdings 0586 | HK$8.83 | HK$14.14 | +60% |
| Mega Union Technology Inc 6944 | 1,005 TWD | 539.58 TWD | -46% |
| MayAir Technology (China) Co 688376 | ¥96.57 | ¥18.80 | -81% |
| Shanghai Emperor of Cleaning Hi-Tech Co 603200 | ¥38.97 | ¥5.73 | -85% |
Compare GVS S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is GVS S.p.A (GVS) overvalued or undervalued?
What is the fair value of GVS?
What is the quality score of GVS?
What is the revenue of GVS S.p.A (GVS)?
What is the net profit margin of GVS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GVS S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.